Multisource Surveillance Study of Pregnancy and Infant Outcomes in Ocrelizumab-Exposed Women With Multiple Sclerosis (MELODIC Study)First published 28/02/2020 Last updated 02/07/2024 EU PAS number: EUPAS33879StudyPlanned